Ceftaroline Fosamil (DB06590): A Comprehensive Clinical and Pharmacological Monograph

Executive Summary

Ceftaroline fosamil is a fifth-generation, parenteral cephalosporin antibiotic distinguished by its unique bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA).[1][ As a water-soluble prodrug, it is rapidly converted]

in vivo to its active metabolite, ceftaroline. The drug's mechanism of action involves the inhibition of bacterial cell wall synthesis through binding to penicillin-binding proteins (PBPs), with a uniquely high affinity for PBP2a, the protein responsible for methicillin resistance in staphylococci.[2]

The United States Food and Drug Administration (FDA) has approved ceftaroline fosamil for two primary indications: the treatment of acute bacterial skin and skin structure infections (ABSSSI), including those caused by MRSA, and community-acquired bacterial pneumonia (CABP).[5] Its efficacy was established in four pivotal Phase III clinical trials. The CANVAS 1 and 2 trials demonstrated non-inferiority to a combination of vancomycin and aztreonam for ABSSSI, with high clinical cure rates against both MSSA and MRSA.[7][ The FOCUS 1 and 2 trials established non-inferiority to ceftriaxone for CABP and showed numerically superior cure rates, particularly in patients with infections caused by]

Streptococcus pneumoniae.[7]

The safety profile of ceftaroline fosamil is generally well-tolerated and consistent with the cephalosporin class. The most common adverse reactions include diarrhea, nausea, and rash.[1][ Key warnings and precautions include the potential for hypersensitivity reactions,]

Clostridioides difficile-associated diarrhea (CDAD), and a notable incidence of direct Coombs' test seroconversion, which necessitates monitoring for potential drug-induced hemolytic anemia.[1][ Neurological adverse events have been reported, primarily in patients with renal impairment who did not receive appropriate dosage adjustments, highlighting the critical importance of dose modification in this population.]

Clinically, ceftaroline fosamil has secured a vital role as a first-line therapeutic option for its approved indications, especially when MRSA is a suspected or confirmed pathogen. Furthermore, a substantial body of evidence from observational studies and systematic reviews documents its extensive and effective off-label use for more complex infections, including bacteremia, endocarditis, and osteomyelitis, often as salvage therapy when standard treatments have failed.[12][ The emergence of ceftaroline-resistant strains, primarily through mutations in the PBP2a target site, underscores the necessity of robust antimicrobial stewardship to preserve the long-term utility of this important agent.]

Introduction and Drug Profile

[Background and Regulatory Status]

Ceftaroline fosamil is a novel, parenteral, fifth-generation cephalosporin antibiotic that represents a significant advancement in the treatment of infections caused by resistant Gram-positive bacteria.[2] It is formulated as a water-soluble N-phosphono prodrug, which undergoes rapid and complete metabolic conversion in the plasma by ubiquitous phosphatase enzymes to its active metabolite, ceftaroline.[4] This chemical modification of the parent compound with a phosphono group was a critical pharmaceutical innovation to enhance water solubility, making it suitable for intravenous administration in a clinical setting.[4]

The drug's development and approval marked a milestone in antibacterial therapy, as it was the first β-lactam antibiotic to be approved in the United States with reliable bactericidal activity against methicillin-resistant Staphylococcus aureus (MRSA). It received initial approval from the U.S. Food and Drug Administration (FDA) on October 29, 2010, for the treatment of ABSSSI and CABP.[4] This was followed by approval from the European Medicines Agency (EMA) in 2012, where it is marketed as Zinforo.[13]

Since its initial approval, the drug's label has been updated to reflect new clinical data and provide greater administration flexibility. In September 2015, the FDA approved a supplemental new drug application that expanded the ABSSSI indication to include patients with baseline S. aureus bacteremia and also approved a shorter intravenous infusion time of five minutes for adult patients, in addition to the standard 60-minute infusion.[16] This shorter infusion time offers significant logistical advantages in various healthcare settings by optimizing the delivery of care.[16] Despite its clinical utility, ceftaroline was removed from the World Health Organization's List of Essential Medicines in 2019, a decision that may reflect considerations of global access, cost, and its specific niche in the antimicrobial armamentarium.[13]

[Chemical and Physical Properties]

Ceftaroline fosamil is classified as a small molecule, synthetic organic compound.[13] Its complex chemical structure is responsible for its unique antimicrobial properties. The full International Union of Pure and Applied Chemistry (IUPAC) name is (6R,7R)-7-[[(2Z)-2-ethoxyimino-2-[5-(phosphonoamino)-1,2,4-thiadiazol-3-yl]acetyl]amino]-3-[[4-(1-methylpyridin-1-ium-4-yl)-1,3-thiazol-2-yl]sulfanyl]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylate.[1][ The key identification and physicochemical properties of the drug are consolidated in Table 1.]

[Table 1: Drug Identification and Properties]

Property	Value	Source(s)
Generic Name	Ceftaroline fosamil	1
DrugBank ID	DB06590	13
CAS Number	229016-73-3	13
Brand Names	Teflaro (U.S.), Zinforo (Europe)	1
Code Designations	PPI-0903, TAK-599	13
Chemical Formula	C22​H21​N8​O8​PS4​	14
Average Molecular Weight	684.67 g/mol	14
Manufacturer	ACS Dobfar spa for Cerexa, Inc. (now part of AbbVie)	17

Comprehensive Pharmacological Profile

[Mechanism of Action and Antimicrobial Spectrum]

[The pharmacological activity of ceftaroline is rooted in its ability to disrupt bacterial cell integrity, a mechanism it shares with other β-lactam antibiotics. However, its chemical structure confers a unique spectrum of activity that sets it apart from previous cephalosporin generations.]

[Core Mechanism]

Like all β-lactams, the primary mechanism of action for ceftaroline is the inhibition of bacterial cell wall biosynthesis. It achieves this by covalently binding to and inactivating essential enzymes known as penicillin-binding proteins (PBPs). These enzymes catalyze the final transpeptidation steps of peptidoglycan synthesis, a process critical for maintaining the structural integrity of the bacterial cell wall. Inhibition of this process leads to cell wall weakening, osmotic instability, and ultimately, bacterial cell lysis and death.[2]

[Unique Anti-MRSA Activity]

The defining characteristic of ceftaroline is its potent bactericidal activity against MRSA, a capability absent in first- through fourth-generation cephalosporins. This unique activity is attributed to its high binding affinity for PBP2a, the modified penicillin-binding protein encoded by the mecA gene, which is the fundamental mechanism of methicillin resistance in Staphylococcus aureus.[4] The molecular structure of ceftaroline, specifically the 1,3-thiazole ring at the 3-position and the oxime group at the C7 acyl moiety, is responsible for this enhanced binding.[4] Unlike other β-lactams that are repelled by the closed conformation of PBP2a, ceftaroline is capable of binding to an allosteric site on the protein. This binding induces a conformational change that opens the active site, allowing a second ceftaroline molecule to access and irreversibly inhibit the transpeptidase domain, thereby overcoming the resistance mechanism.[4]

[Activity Against Streptococcus pneumoniae]

In addition to its anti-MRSA activity, ceftaroline demonstrates high affinity for other critical PBPs, notably PBP2x in Streptococcus pneumoniae. This high affinity explains its potent activity against penicillin-resistant S. pneumoniae (PRSP) and multidrug-resistant strains, making it a highly effective agent for community-acquired bacterial pneumonia caused by this pathogen.[4]

[Spectrum of Activity]

[The antimicrobial spectrum of ceftaroline is broad, encompassing key Gram-positive and select Gram-negative pathogens.]

• Gram-Positive Organisms: Ceftaroline exhibits potent in vitro activity against a wide range of Gram-positive bacteria. This includes Staphylococcus aureus (both MSSA and MRSA), including strains with reduced susceptibility or resistance to vancomycin (VISA), linezolid, and daptomycin.[3] It is also highly active against common streptococcal species, such as Streptococcus pneumoniae (including penicillin-susceptible, penicillin-resistant, and multidrug-resistant isolates), Streptococcus pyogenes (Group A Streptococcus), and Streptococcus agalactiae (Group B Streptococcus).[4]
• Gram-Negative Organisms: Its Gram-negative spectrum is comparable to that of third-generation cephalosporins like ceftriaxone. It has good activity against common respiratory and community-associated pathogens such as Haemophilus influenzae (including β-lactamase-producing strains), Moraxella catarrhalis, Escherichia coli, and Klebsiella pneumoniae.[4] However, ceftaroline is not active against Pseudomonas aeruginosa or Enterobacterales that produce extended-spectrum β-lactamases (ESBLs) or AmpC β-lactamases, which limits its utility for many hospital-acquired Gram-negative infections.[23]

[Pharmacodynamics (PD)]

The bactericidal effect of ceftaroline, like other β-lactam antibiotics, is primarily time-dependent. The critical pharmacokinetic/pharmacodynamic (PK/PD) index that correlates with clinical and microbiological efficacy is the percentage of the dosing interval during which the free (unbound) drug concentration remains above the minimum inhibitory concentration (MIC) of the target pathogen, expressed as %fT>MIC.[15]

Extensive preclinical studies, including animal infection models and in vitro simulations, have been used to define the magnitude of this index required for optimal bactericidal activity. These studies have established that the standard dosing regimens are designed to achieve a high probability of target attainment against susceptible pathogens. For S. aureus, a PK/PD target of approximately 36% fT>MIC is associated with a 1-log reduction in bacterial density, while for S. pneumoniae, a slightly higher target of 44% fT>MIC is required for similar efficacy.[26] The approved dosing regimens for adults and children are calculated to reliably achieve these targets for organisms with MIC values up to 1 mg/L, ensuring a high likelihood of therapeutic success against susceptible strains.[26]

[Pharmacokinetics (PK)]

[The pharmacokinetic profile of ceftaroline has been well-characterized in healthy volunteers and patient populations, demonstrating predictable and linear behavior.]

[Absorption]

Ceftaroline fosamil is administered exclusively via the intravenous route. Following administration, the prodrug is rapidly and completely hydrolyzed by plasma phosphatases into the active ceftaroline moiety.[14] The pharmacokinetics of active ceftaroline are linear and dose-proportional, meaning that key exposure parameters such as the maximum plasma concentration (Cmax) and the area under the concentration-time curve (AUC) increase proportionally with increasing doses within the clinically relevant range.[4] No significant drug accumulation is observed with multiple doses administered every 12 hours in individuals with normal renal function.[5]

[Distribution]

Ceftaroline exhibits favorable distribution characteristics. It has low binding to human plasma proteins, at approximately 20%, which allows a high fraction of the drug to remain free and biologically active.[5] The steady-state volume of distribution (Vd) in healthy adults is approximately 20.3 L, a value comparable to the volume of the body's extracellular fluid, suggesting that the drug distributes well from the plasma into tissues.[5] Studies have also confirmed its ability to penetrate effectively into bone tissue, which supports its use in treating osteomyelitis.[28]

[Metabolism]

The metabolic profile of ceftaroline is a key feature contributing to its favorable safety and drug interaction profile. The conversion of the ceftaroline fosamil prodrug to active ceftaroline is the primary metabolic step and occurs rapidly in the plasma.[4][ The active ceftaroline molecule itself does not undergo significant hepatic metabolism.]

In vitro studies using human liver microsomes have shown that it is not a substrate for Cytochrome P450 (CYP450) enzymes.[5] This lack of reliance on the CYP450 system for metabolism is a significant clinical advantage. It means that the potential for drug-drug interactions with co-administered medications that are inhibitors, inducers, or substrates of this enzyme system is minimal. This simplifies prescribing for complex patients on multiple medications, a common scenario in the hospital setting where ceftaroline is used. A minor metabolic pathway exists where the β-lactam ring of ceftaroline is hydrolyzed to form an open-ring, microbiologically inactive metabolite known as ceftaroline M-1.[5]

[Excretion]

Ceftaroline is eliminated from the body primarily through the kidneys.[5] Following a single intravenous dose, approximately 88% of the drug is recovered in the urine within 48 hours, with about 64% as unchanged active ceftaroline and a small fraction (~2%) as the inactive M-1 metabolite. A minor portion (~6%) is eliminated via the feces.[5] The mean renal clearance of ceftaroline suggests that it is predominantly cleared by glomerular filtration. In healthy adults with normal renal function, the elimination half-life is approximately 2.6 hours.[5][ This renal-dependent elimination pathway necessitates careful dose adjustments in patients with impaired renal function to prevent drug accumulation and potential toxicity. This direct link between renal function, drug clearance, and risk of adverse events makes adherence to renal dosing guidelines a critical component of safe and effective therapy.]

[Table 2: Summary of Key Pharmacokinetic Parameters in Adults (600 mg IV over 1 hour)]

Parameter	Value	Source(s)
Cmax (Peak Plasma Concentration)	~17.4 mcg/mL	5
AUC (Area Under the Curve)	~65-67 μg·h/mL	29
Vd (Volume of Distribution)	~20.3 L	5
Plasma Protein Binding	~20%	5
Elimination Half-Life (t1/2​)	~2.6 hours	27
Primary Route of Elimination	Renal (~88% in urine)	5

Clinical Efficacy and Therapeutic Applications

[FDA-Approved Indications]

[Ceftaroline fosamil is approved by the U.S. FDA for the treatment of two specific and common infectious diseases, with indications extending to both adult and pediatric populations.]

• Acute Bacterial Skin and Skin Structure Infections (ABSSSI): Ceftaroline is indicated for the treatment of ABSSSI in adult and pediatric patients (defined as individuals of at least 34 weeks gestational age and 12 days postnatal age). The approved spectrum for this indication includes susceptible isolates of Staphylococcus aureus (both methicillin-susceptible and methicillin-resistant), Streptococcus pyogenes, Streptococcus agalactiae, Escherichia coli, Klebsiella pneumoniae, and Klebsiella oxytoca.[5]
• Community-Acquired Bacterial Pneumonia (CABP): Ceftaroline is indicated for the treatment of CABP in adult and pediatric patients two months of age and older. The approved spectrum for this indication includes susceptible isolates of Streptococcus pneumoniae (including cases with concurrent bacteremia), Staphylococcus aureus (methicillin-susceptible isolates only), Haemophilus influenzae, Klebsiella pneumoniae, Klebsiella oxytoca, and Escherichia coli.[5]

A crucial component of the drug's labeling is the emphasis on antimicrobial stewardship. The FDA prescribing information explicitly states that to reduce the development of drug-resistant bacteria, ceftaroline should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria.[1]

[Analysis of Pivotal Clinical Trials (CANVAS & FOCUS)]

The regulatory approval of ceftaroline fosamil was based on a robust clinical development program comprising four large, randomized, double-blind, multicenter Phase III trials. The efficacy and safety for ABSSSI were established in the CANVAS 1 and CANVAS 2 trials, while the FOCUS 1 and FOCUS 2 trials provided the evidence for its use in CABP.[7]

[CANVAS 1 & 2 Trials (ABSSSI)]

The CANVAS (Ceftaroline versus Vancomycin in Skin and Skin Structure Infections) trials were designed to assess the efficacy of ceftaroline monotherapy compared to a standard-of-care combination therapy for complicated skin and skin structure infections (now referred to as ABSSSI).[8]

• Design: These two nearly identical trials (NCT00424190 and NCT00423657) randomized adult patients to receive either ceftaroline fosamil (600 mg IV every 12 hours) or a combination of vancomycin (1 g IV every 12 hours) plus aztreonam (1 g IV every 12 hours). The aztreonam component was included to provide Gram-negative coverage comparable to that of ceftaroline. Treatment duration was 5 to 14 days.[8]
• Efficacy: The primary objective was to demonstrate non-inferiority. In an integrated analysis of the clinically evaluable (CE) populations from both trials, ceftaroline fosamil was found to be non-inferior to the vancomycin/aztreonam regimen. The clinical cure rates were 91.6% for the ceftaroline group and 92.7% for the comparator group.[23] A critical finding of these trials was the high efficacy of ceftaroline against MRSA. In the subgroup of patients with MRSA infections, the clinical cure rates were 93.4% for ceftaroline and 94.3% for vancomycin/aztreonam, demonstrating that ceftaroline monotherapy was as effective as the standard anti-MRSA agent, vancomycin.[7]

[FOCUS 1 & 2 Trials (CABP)]

The FOCUS (FOCUS 1: NCT00621504, FOCUS 2: NCT00509106) trials were designed to evaluate ceftaroline for the treatment of moderate-to-severe CABP requiring hospitalization.[7]

• Design: These trials randomized adult patients with Pneumonia Outcomes Research Team (PORT) Risk Class III or IV to receive either ceftaroline fosamil (600 mg IV every 12 hours) or ceftriaxone (1 g IV every 24 hours), a standard treatment for CABP. Treatment duration was 5 to 7 days.[7]
• Efficacy: Ceftaroline successfully met the primary endpoint of non-inferiority to ceftriaxone. An integrated analysis of the CE population revealed a numerically higher clinical cure rate for ceftaroline (84.3%) compared to ceftriaxone (77.7%).[7] This difference was particularly pronounced and clinically significant in the subgroup of patients with CABP caused by S. pneumoniae, the most common causative pathogen. In this group, the clinical cure rate was markedly higher with ceftaroline (85.5%) than with ceftriaxone (68.6%).[7][ This finding suggests that for patients with confirmed or highly suspected pneumococcal pneumonia, ceftaroline may offer a therapeutic advantage over the standard-of-care third-generation cephalosporins, moving beyond simple non-inferiority.]

[Table 3: Efficacy Outcomes from Pivotal Phase III Trials (CANVAS & FOCUS)]

Trial Program	Indication	Ceftaroline Arm	Comparator Arm	Primary Efficacy Outcome (Population)	Clinical Cure Rate
CANVAS 1 & 2	ABSSSI	Ceftaroline 600 mg q12h	Vancomycin 1g q12h + Aztreonam 1g q12h	Overall Clinical Cure (CE)	91.6% vs. 92.7% 23
				MRSA Clinical Cure (ME)	93.4% vs. 94.3% 7
FOCUS 1 & 2	CABP	Ceftaroline 600 mg q12h	Ceftriaxone 1g q24h	Overall Clinical Cure (CE)	84.3% vs. 77.7% 7
				S. pneumoniae Clinical Cure (ME)	85.5% vs. 68.6% 7
CE = Clinically Evaluable; ME = Microbiologically Evaluable

[Off-Label and Investigational Uses]

The unique anti-MRSA activity and favorable safety profile of ceftaroline have led to its widespread off-label use in clinical practice, particularly for severe or refractory infections where standard therapies have failed or are contraindicated.[12][ This extensive real-world experience, while not derived from randomized controlled trials, provides valuable information on the broader clinical utility of the drug.]

A comprehensive systematic review published in 2019 analyzed 21 studies encompassing 1,901 patients treated with ceftaroline for off-label indications. The most common reasons for its use were persistent or recurrent infection despite standard therapy or documented non-susceptibility to first-line agents like vancomycin and daptomycin. The most frequently reported off-label uses included [12][:]

• Bacteremia[ (n=595)]
• Osteoarticular Infections[ (n=368)]
• Infective Endocarditis[ (n=171)]
• Hospital-Acquired Pneumonia (HAP)[ (n=115)]
• Meningitis[ (n=23)]

Across these challenging and heterogeneous patient populations, the overall clinical success rate was a notable 77%.[12][ This body of evidence suggests that clinical practice has, in effect, expanded ceftaroline's role beyond its formal regulatory approvals, positioning it as a critical salvage therapy agent.]

• Bacteremia and Endocarditis: Ceftaroline is often employed as salvage therapy for persistent MRSA bacteremia and infective endocarditis.[12] While it is not FDA-approved for primary bacteremia, the 2015 label update acknowledging its use in ABSSSI with concurrent S. aureus bacteremia provides some regulatory support for its activity in the bloodstream.[16] Various case series and small trials report clinical success rates ranging from 50% to over 83% in these difficult-to-treat infections.[37]
• Osteomyelitis: The use of ceftaroline for osteomyelitis is supported by its favorable bone penetration and strong clinical data from observational studies.[28] The CAPTURE (Clinical Assessment Program and Teflaro® Utilization Registry) study, a large retrospective analysis, reported a high clinical success rate of 92.7% among 150 patients treated for Gram-positive osteomyelitis.[28] A Phase IV clinical trial (NCT02005068) was initiated to formally evaluate its use in bone and joint infections but was later withdrawn, leaving a critical evidence gap.[40][ The absence of a definitive randomized trial means clinicians must continue to rely on lower-level, albeit promising, observational evidence for this indication.]
• Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP): Data from the CAPTURE registry also provided insights into the use of ceftaroline for HAP and VAP. In a cohort of 40 patients, the overall clinical success rate was 75% (82% for HAP and 62% for VAP).[41] These findings position ceftaroline as a potential alternative to vancomycin or linezolid for the treatment of nosocomial pneumonia caused by MRSA.[42]

Safety, Tolerability, and Risk Management

[The safety profile of ceftaroline fosamil has been extensively evaluated in clinical trials involving over 1,700 patients and through post-marketing surveillance. It is generally well-tolerated, with a safety profile consistent with the broader cephalosporin class.]

[Adverse Drug Reactions (ADRs)]

• Common ADRs: In pooled analyses of the four pivotal Phase III trials in adults, no single adverse reaction occurred in more than 5% of patients. The most frequently reported ADRs (occurring in >2% of patients) were diarrhea (5%), nausea (4%), and rash (3%).[1] In the pooled pediatric trials, the most common ADRs (≥3%) were diarrhea (8%), rash (7%), and vomiting (5%).[11][ A detailed comparison of common ADRs in adults is provided in Table 4.]
• Serious ADRs: The incidence of serious adverse reactions in adult clinical trials was comparable between the ceftaroline and comparator groups (7.5% vs. 7.7%, respectively).[44] The rate of treatment discontinuation due to adverse events was low and slightly favored ceftaroline (2.7%) over the comparator drugs (3.7%). Hypersensitivity was the most common adverse reaction leading to discontinuation in both groups.[11] Importantly, dedicated studies have shown no significant effect of ceftaroline on the QTc interval.[14]

[Table 4: Incidence of Common Adverse Reactions (≥2%) in Pooled Adult Clinical Trials]

Adverse Reaction	Ceftaroline (N=1300)	Pooled Comparators (N=1297)	Source(s)
Diarrhea	5%	3%	5
Nausea	4%	4%	5
Rash	3%	2%	5
Vomiting	2%	2%	44
Increased Transaminases	2%	3%	5
Hypokalemia	2%	3%	5
Phlebitis	2%	1%	5
Constipation	2%	2%	44

[Contraindications, Warnings, and Precautions]

[The use of ceftaroline requires adherence to several key safety considerations, many of which are common to the β-lactam class.]

• Contraindications: Ceftaroline is contraindicated in patients with a known history of serious hypersensitivity (e.g., anaphylaxis) to ceftaroline or other cephalosporin-class antibiotics.[1]
• Hypersensitivity Reactions: As with all β-lactam antibiotics, serious and occasionally fatal hypersensitivity reactions can occur. A careful inquiry regarding previous allergic reactions to penicillins, carbapenems, or other cephalosporins should be made before initiating therapy. Due to established cross-sensitivity among β-lactams, caution is warranted when administering ceftaroline to patients with a history of penicillin allergy. If an allergic reaction occurs, the drug must be discontinued immediately and appropriate emergency treatment instituted.[1]
• Clostridioides difficile-Associated Diarrhea (CDAD): CDAD has been reported with nearly all systemic antibacterial agents, including ceftaroline. The severity can range from mild diarrhea to life-threatening pseudomembranous colitis. CDAD should be considered in any patient who presents with diarrhea following antibiotic use, as it can occur more than two months after administration. If CDAD is suspected or confirmed, discontinuation of ceftaroline may be necessary.[1]
• Direct Coombs' Test (DAGT) Seroconversion: A notable laboratory finding associated with ceftaroline is a relatively high rate of seroconversion to a positive direct Coombs' test. In pooled adult trials, this occurred in 9.8% to 11.2% of patients receiving standard doses of ceftaroline, a rate more than double that observed in comparator groups (~4.5%).[1] The incidence increases substantially with higher-frequency dosing, reaching 32.3% in patients receiving the drug every 8 hours.[46] While drug-induced hemolytic anemia was not reported during the pivotal clinical trials, a positive DAGT is a potential precursor. Therefore, this is not merely a benign lab abnormality but a clear signal for clinical vigilance. Any patient who develops anemia during or after treatment with ceftaroline should be evaluated for the possibility of drug-induced hemolytic anemia.[1]
• Neurological Adverse Reactions: Post-marketing surveillance has identified cases of neurological adverse reactions, including encephalopathy and seizures. These events have occurred predominantly in patients with pre-existing renal impairment who did not receive the recommended dose adjustments. These reactions are typically reversible upon discontinuation of the drug or after hemodialysis. This establishes a direct causal link between renal impairment, drug accumulation, and central nervous system toxicity, underscoring the critical importance of proper renal dose adjustment.[11]
• Development of Drug-Resistant Bacteria: The prescribing information includes a standard warning that using ceftaroline in the absence of a proven or strongly suspected bacterial infection is unlikely to benefit the patient and increases the risk of the development of drug-resistant bacteria.[1]

[Clinically Significant Drug-Drug Interactions]

While no formal clinical drug-drug interaction studies have been conducted with ceftaroline, its pharmacokinetic profile allows for a well-reasoned assessment of potential risks.[11]

• Cytochrome P450 (CYP450) System: The risk of metabolic drug interactions is very low. In vitro studies have demonstrated that ceftaroline is neither a substrate, an inhibitor, nor an inducer of the major CYP450 isoenzymes.[5][ This provides a high degree of confidence that clinically significant interactions with drugs metabolized through this pathway are unlikely.]
• Renal Excretion Pathways: Since ceftaroline is primarily eliminated by the kidneys, the main potential for drug interactions lies in competition for renal clearance mechanisms. Co-administration with other drugs that undergo active renal secretion or that alter renal blood flow could theoretically alter the plasma concentrations of either ceftaroline or the concomitant drug.[11] DrugBank data suggest that ceftaroline may decrease the excretion rate of numerous other renally-cleared drugs, such as acetaminophen, allopurinol, and amoxicillin, though the clinical significance of these potential interactions has not been established.[14]
• Nephrotoxicity: There is a potential for an additive nephrotoxic effect when ceftaroline is co-administered with other known nephrotoxic agents, such as aminoglycosides (e.g., gentamicin) or certain nonsteroidal anti-inflammatory drugs.[14]
• Bleeding Risk: Co-administration with anticoagulants (e.g., acenocoumarol) may increase the risk of bleeding.[14] Unlike some older cephalosporins (e.g., cefotetan), ceftaroline does not possess the N-methylthiotetrazole (MTT) side chain that is strongly associated with hypoprothrombinemia; however, general caution is still warranted when used with anticoagulants.[27]

Dosage, Administration, and Special Populations

[Dosing and Administration Guidelines]

[The dosing and administration of ceftaroline fosamil vary based on the indication, patient age, body weight, and renal function.]

• Standard Adult Dosing (ABSSSI & CABP): The recommended dosage for adults (≥18 years of age) with normal renal function is 600 mg administered every 12 hours (q12h) by intravenous (IV) infusion.[5]
• High-Dose Adult Regimen: In some regions, a high-dose regimen of 600 mg every 8 hours (q8h) administered as a 120-minute infusion is recommended for the treatment of complicated skin and soft tissue infections (cSSTI) confirmed or suspected to be caused by S. aureus with a ceftaroline MIC of 2 or 4 mg/L. This recommendation is based on PK/PD modeling to optimize target attainment for less susceptible isolates.[46]
• Pediatric Dosing: Dosing in pediatric patients is stratified by age and weight to achieve exposures comparable to those in adults. Representative regimens include: 6 mg/kg q8h for neonates and infants up to 2 months; 8 mg/kg q8h for infants 2 months to <2 years; 12 mg/kg q8h for children 2 to <18 years weighing ≤33 kg; and either 400 mg q8h or 600 mg q12h for children weighing >33 kg.[49]
• Administration: Ceftaroline fosamil is supplied as a sterile powder for reconstitution. The powder in the vial must first be reconstituted with 20 mL of a compatible diluent (e.g., Sterile Water for Injection, 0.9% Sodium Chloride). The resulting solution must then be further diluted in a 50 mL to 250 mL infusion bag containing a compatible IV solution (e.g., 0.9% Sodium Chloride, 5% Dextrose).[5] The final infusion is administered intravenously. The infusion time for standard doses in adults and children over 2 months is 5 to 60 minutes.[5] The approval of the shorter 5-minute infusion time in adults provides a significant logistical advantage, enabling more flexible and efficient administration in busy clinical environments like emergency departments or outpatient infusion centers without compromising systemic exposure (AUC).[5] For high-dose regimens, a longer 120-minute infusion is required.[46]

[Dosage Adjustments for Organ Dysfunction]

[Proper dose adjustment is essential for the safe use of ceftaroline, particularly in patients with renal impairment.]

• Renal Impairment:[ As ceftaroline is primarily cleared by the kidneys, dosage adjustments are critical to prevent drug accumulation and the associated risk of toxicity, especially neurological adverse events. No adjustment is necessary for patients with a creatinine clearance (CrCl) >50 mL/min. Specific recommendations for adult patients with renal impairment are detailed in Table 5.]

[Table 5: Recommended Dosage Adjustments in Adult Renal Impairment]

Creatinine Clearance (CrCl)	Recommended Dosage Regimen	Source(s)
> 50 mL/min	600 mg IV every 12 hours (No adjustment)	45
> 30 to ≤ 50 mL/min	400 mg IV every 12 hours	45
≥ 15 to ≤ 30 mL/min	300 mg IV every 12 hours	45
< 15 mL/min (ESRD), including hemodialysis	200 mg IV every 12 hours	45

• Note on Hemodialysis: Ceftaroline is hemodialyzable. On hemodialysis days, the dose should be administered after the dialysis session is complete to ensure the patient receives the full therapeutic dose.[15]
• Hepatic Impairment: The pharmacokinetics of ceftaroline have not been formally studied in patients with hepatic impairment. However, because the drug does not undergo significant hepatic metabolism, its clearance is not expected to be affected by liver dysfunction, and therefore, no dosage adjustment is recommended for this population.[5]
• Geriatric Use (≥65 years): No dose adjustment is required based on age alone. However, elderly patients frequently have age-related declines in renal function. Therefore, dose selection in this population should be guided by the individual patient's estimated creatinine clearance, following the recommendations for renal impairment.[5]

Comparative Analysis and Place in Therapy

[Ceftaroline fosamil occupies a distinct and important niche in the antimicrobial armamentarium. Its clinical value is best understood through comparison with other key agents used for infections caused by resistant Gram-positive pathogens, particularly MRSA.]

[Comparison with Vancomycin and Linezolid]

[Vancomycin has long been the workhorse for treating serious MRSA infections, while linezolid offers an alternative with different properties.]

• Efficacy: In the pivotal CANVAS trials for ABSSSI, ceftaroline monotherapy was demonstrated to be non-inferior to vancomycin (in combination with aztreonam) for treating infections caused by MRSA, establishing its credentials as a first-line alternative.[8] For MRSA pneumonia, where vancomycin's efficacy can be limited by poor lung tissue penetration, both linezolid and ceftaroline are considered strong alternatives.[42] A recent meta-analysis suggested that linezolid may offer superior clinical outcomes compared to vancomycin for pneumonia.[52] In vitro, ceftaroline is consistently bactericidal, whereas vancomycin's activity can be slow or even bacteriostatic against some MRSA strains, particularly those with higher MICs.[36]
• Safety and Practicality: Ceftaroline holds several practical advantages over vancomycin. It does not require therapeutic drug monitoring (TDM) to ensure efficacy and avoid toxicity, a labor-intensive and costly process essential for vancomycin therapy.[42] Furthermore, ceftaroline avoids the significant risk of nephrotoxicity associated with vancomycin.[42] Compared to linezolid, ceftaroline avoids the risks of myelosuppression (particularly thrombocytopenia with prolonged use) and serotonin syndrome, a serious drug interaction risk in patients taking serotonergic agents.[42][ As a bactericidal agent, ceftaroline may also be preferred over the bacteriostatic linezolid for severe, deep-seated infections like endocarditis.]

[Comparison with Daptomycin]

[Daptomycin is a rapidly bactericidal lipopeptide antibiotic and another key alternative for serious MRSA infections.]

• Efficacy: A large, multicenter retrospective cohort study directly comparing ceftaroline to daptomycin for the treatment of MRSA bacteremia found that ceftaroline was non-inferior with respect to a composite outcome of treatment failure, with no significant difference in 30-day mortality.[55] A critical differentiating factor is the site of infection: daptomycin is inactivated by pulmonary surfactant and is therefore ineffective for treating pneumonia, whereas ceftaroline is FDA-approved for CABP.[55]
• Combination Therapy and Synergy: The most significant development in the clinical use of these two drugs is the recognition of their powerful synergistic activity. Numerous in vitro studies and clinical case series have demonstrated that the combination of ceftaroline and daptomycin is highly effective for treating persistent or refractory MRSA bacteremia, including infections caused by daptomycin-nonsusceptible strains.[36][ The addition of ceftaroline appears to enhance daptomycin's ability to bind to the bacterial cell membrane, leading to rapid and sustained bactericidal killing. This has led to a paradigm shift where ceftaroline's role is evolving from solely a monotherapy agent to a critical component of combination salvage therapy for the most difficult-to-treat MRSA infections.]

[Unique Position Among Cephalosporins]

Ceftaroline's primary distinction is its status as the first cephalosporin approved in the U.S. with reliable, potent bactericidal activity against MRSA.[1] This capability is a direct result of its high affinity for the mutated PBP2a and fundamentally separates it from all prior generations of cephalosporins, which are clinically ineffective against MRSA.[20][ This unique attribute carves out a therapeutic niche that other cephalosporins cannot fill, allowing clinicians to use a familiar and generally well-tolerated β-lactam agent for infections that previously required entirely different classes of antibiotics.]

[The optimal choice of an anti-MRSA agent is not universal but is a nuanced decision based on a matrix of factors including the site of infection, pathogen susceptibility (MIC values), and patient-specific comorbidities and risk factors. Table 6 provides a comparative summary to aid in this clinical decision-making process.]

[Table 6: Comparative Profile of Key Anti-MRSA Antibiotics]

Feature	Ceftaroline	Vancomycin	Linezolid	Daptomycin
Drug Class	Cephalosporin (β-lactam)	Glycopeptide	Oxazolidinone	Cyclic Lipopeptide
Bactericidal Activity	Bactericidal	Bactericidal (often slow)	Bacteriostatic	Rapidly Bactericidal
Key Advantage	Anti-MRSA β-lactam activity; No TDM	Low cost; Decades of experience	Oral option; Excellent tissue/lung penetration	Rapid killing; Activity against VRE
Key Disadvantage / Toxicity	Neutropenia (prolonged use); Rash	Nephrotoxicity; TDM required; Poor lung penetration	Myelosuppression; Serotonin syndrome; Peripheral neuropathy	Inactivated by pulmonary surfactant; CPK elevation/myopathy
Sources: 20

Antimicrobial Resistance and Stewardship

[The long-term clinical utility of any antibiotic is threatened by the inevitable emergence of bacterial resistance. For ceftaroline, understanding the mechanisms of resistance and monitoring susceptibility trends are paramount for effective antimicrobial stewardship.]

[Mechanisms of Resistance]

The primary mechanism by which S. aureus[ develops resistance to ceftaroline involves modifications to its direct molecular target, PBP2a. This is a classic example of target-site modification, a common evolutionary strategy for bacteria under antibiotic pressure.]

• PBP2a Mutations: Resistance is primarily mediated by point mutations in the mecA gene, which result in amino acid substitutions in the PBP2a protein.[21] These mutations can occur both within the transpeptidase (penicillin-binding) domain and, crucially, within the allosteric (non-penicillin-binding) domain. Substitutions in the allosteric domain, such as the N146K and E150K mutations identified in clinical isolates, can prevent the conformational change that ceftaroline needs to induce to open the active site, thereby blocking its inhibitory activity.[21] Mutations in other PBPs, such as PBP3 and PBP4, can also contribute to reduced susceptibility.[24]
• Gram-Negative Resistance: In Gram-negative bacteria like E. coli, an emerging resistance mechanism involves mutations in the ftsI gene, which encodes PBP3. These mutations can lead to the insertion of additional amino acids (e.g., YRIN or YRIK) near the active site, reducing the binding affinity of β-lactam antibiotics, including cephalosporins.[60]

[Surveillance Data and Susceptibility Trends]

[Ongoing surveillance programs are essential for tracking the susceptibility of key pathogens to ceftaroline.]

• Early Surveillance (AWARE Program, 2010): Shortly after its launch, the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) surveillance program provided baseline susceptibility data from the United States. In 2010, ceftaroline demonstrated excellent activity, with 98.4% of MRSA isolates found to be susceptible (defined by an MIC ≤1 µg/mL).[61] This high level of activity was consistent across all nine U.S. census regions.[63]
• Emergence of Resistance: While ceftaroline remains highly active against most staphylococci, including many strains with reduced susceptibility to other agents, reports of resistance began to emerge within years of its introduction.[24] Clinically significant resistance has been documented in isolates from patients undergoing prolonged or repeated courses of therapy, such as those with cystic fibrosis or persistent endocarditis.[24] A 2022 study focusing on pediatric invasive MRSA infections identified a reduced susceptibility rate of 2.9%, exclusively among healthcare-associated isolates.[65]
• Recent Global Trends (2017-2020): More recent global surveillance data on bloodstream isolates from 2017-2020 indicate a global MRSA susceptibility rate to ceftaroline of 89.8%.[66][ While still high, this represents a discernible decline from the >98% susceptibility observed a decade prior. This slow but steady erosion highlights that the "honeymoon period" of near-universal activity is ending and underscores the need for vigilant stewardship.]
• Cross-Resistance: Interestingly, the newer anti-MRSA cephalosporin, ceftobiprole, appears to retain activity against a significant majority (87.3%) of ceftaroline-nonsusceptible MRSA isolates, suggesting it may serve as a potential therapeutic option when ceftaroline resistance is encountered.[67]

[Implications for Antimicrobial Stewardship]

[The documented mechanisms of resistance and the observed trends in susceptibility have direct implications for antimicrobial stewardship programs.]

• Judicious Use: The emergence of target-site resistance mutations reinforces the principle that ceftaroline should be used judiciously to preserve its efficacy for as long as possible.[24][ This includes adhering to the FDA's recommendation to use it only for proven or strongly suspected susceptible bacterial infections.]
• Clinical Positioning:[ Stewardship programs should work to position ceftaroline appropriately in institutional guidelines. It serves as a valuable first-line agent for its approved indications when MRSA is a concern. For off-label uses, it should be considered a carefully selected alternative or salvage therapy, often guided by infectious diseases consultation, particularly for severe infections where first-line agents have failed. Its role in combination with daptomycin for refractory bacteremia is an important stewardship consideration.]
• Ongoing Monitoring: Continued participation in and monitoring of data from local, national, and global surveillance programs is essential to track emerging resistance trends and to inform and update institutional antibiograms and treatment guidelines.[61]

Conclusion and Future Directions

Ceftaroline fosamil is a landmark achievement in the field of antibacterial chemotherapy. As a fifth-generation cephalosporin, it successfully addressed a critical unmet need by providing a well-tolerated and effective β-lactam option for the treatment of serious infections caused by MRSA and multidrug-resistant Streptococcus pneumoniae[. Its clinical efficacy and safety are firmly established for its approved indications of acute bacterial skin and skin structure infections and community-acquired bacterial pneumonia, supported by a robust program of Phase III clinical trials.]

[The primary clinical value of ceftaroline lies in its unique ability to treat MRSA infections with the familiar safety profile of a cephalosporin, avoiding the need for therapeutic drug monitoring associated with vancomycin and the specific toxicities of linezolid and daptomycin. Beyond its approved indications, a growing body of real-world evidence has established its role as an indispensable salvage therapy for severe and refractory infections, including bacteremia, infective endocarditis, and osteomyelitis. However, its use must be tempered by careful attention to its safety profile, particularly the risk of hypersensitivity reactions, the high rate of direct Coombs' test seroconversion, and the critical need for dosage adjustment in patients with renal impairment to prevent neurological toxicity.]

[Despite its established role, significant evidence gaps remain. The future of ceftaroline therapy and research should be directed toward addressing these gaps to optimize its use and preserve its long-term efficacy. Key future directions include:]

1. Conducting Randomized Controlled Trials for Off-Label Uses:[ The most pressing need is for high-quality, randomized controlled trials (RCTs) to formally evaluate the efficacy and safety of ceftaroline for its most common off-label uses. Priority should be given to trials comparing ceftaroline to the standard of care (e.g., daptomycin) for MRSA bacteremia and infective endocarditis, and an RCT for osteomyelitis is needed to confirm the highly promising results from current observational data.]
2. Optimizing Combination Therapy:[ The synergistic combination of ceftaroline and daptomycin has become a cornerstone of salvage therapy for persistent MRSA bacteremia. Future research should focus on defining the optimal timing, dosing, and duration of this combination therapy to maximize efficacy while minimizing toxicity and cost.]
3. Vigilant Resistance Surveillance:[ The emergence of ceftaroline-resistant MRSA through target-site mutations is the single greatest threat to its continued utility. Robust, ongoing global surveillance programs are essential to monitor the prevalence and spread of these resistant strains. This data is critical for informing treatment guidelines and guiding stewardship efforts.]

[In conclusion, ceftaroline fosamil remains a vital tool in the management of serious Gram-positive infections. Its continued value will depend on a concerted effort by clinicians and researchers to use it judiciously, to formally validate its role in severe infections through rigorous clinical trials, and to vigilantly monitor for the emergence of resistance.]

Works cited

1. Ceftaroline fosamil - Wikipedia, accessed August 6, 2025, https://en.wikipedia.org/wiki/Ceftaroline_fosamil
2. Ceftaroline: A New Cephalosporin with Activity against Methicillin, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3140339/
3. Ceftaroline fosamil: a new cephalosporin active against resistant Gram-positive organisms including MRSA - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/23167512/
4. Ceftaroline fosamil: a new broad-spectrum cephalosporin | Journal ..., accessed August 6, 2025, https://academic.oup.com/jac/article/66/suppl_3/iii11/669100
5. TEFLARO® (ceftaroline fosamil) for injection, for intravenous use, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2015/200327s015lbl.pdf
6. TEFLARO® (ceftaroline fosamil) Resources, accessed August 6, 2025, https://www.teflaro.com/resourses
7. Summary of Ceftaroline Fosamil Clinical Trial Studies and Clinical ..., accessed August 6, 2025, https://academic.oup.com/cid/article/55/suppl_3/S173/285518
8. CANVAS 1: the first Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/21115454/
9. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/21115455/
10. FOCUS 1: a randomized, double-blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/21482566/
11. TEFLARO® (ceftaroline fosamil) Pediatric Safety Profile, accessed August 6, 2025, https://www.teflaro.com/pediatric/safety-profile
12. Off-label use of ceftaroline fosamil: A systematic review - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/31279152/
13. ceftaroline fosamil | Ligand page - IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 6, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=10899
14. Ceftaroline fosamil: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 6, 2025, https://go.drugbank.com/drugs/DB06590
15. [Pharmacokinetics and pharmacodynamics of ceftaroline] - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/24702974/
16. Allergan Announces FDA Approval Of Updated Label For TEFLARO (ceftaroline fosamil), accessed August 6, 2025, https://www.biospace.com/allergan-announces-fda-approval-of-updated-label-for-teflaro-ceftaroline-fosamil
17. CEFTAROLINE FOSAMIL, accessed August 6, 2025, https://searchusan.ama-assn.org/usan/documentDownload?uri=/unstructured/binary/usan/ceftaroline_fosamil.pdf
18. TEFLARO® Programs, Support & Resources - AbbVie Access, accessed August 6, 2025, https://www.abbvieaccess.com/brand/teflaro
19. pmc.ncbi.nlm.nih.gov, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3140339/#:~:text=Like%20other%20%CE%B2%2Dlactams%2C%20ceftaroline's,of%20the%20bacterial%20cell%20wall.
20. Ceftaroline: A Novel Cephalosporin with Activity against Methicillin-resistant Staphylococcus aureus | Clinical Infectious Diseases | Oxford Academic, accessed August 6, 2025, https://academic.oup.com/cid/article/52/9/1156/319588
21. Unraveling the mechanism of ceftaroline-induced allosteric regulation in penicillin-binding protein 2a: insights for novel antibiotic development against methicillin-resistant Staphylococcus aureus - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10720500/
22. Pharmacokinetic and pharmacodynamic evaluation of ceftaroline fosamil - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/25347329/
23. Large Retrospective Evaluation of the Effectiveness and Safety of Ceftaroline Fosamil Therapy - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3993242/
24. Resistance to ceftaroline - 2018 review - CORE, accessed August 6, 2025, https://core.ac.uk/download/pdf/296524013.pdf
25. Ceftaroline Fosamil: A Brief Clinical Review - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4108109/
26. N200327S0160 - 17 Ceftaroline fosamil Clinpharm PREA - FDA, accessed August 6, 2025, https://www.fda.gov/files/drugs/published/N200327S0160---17-Ceftaroline-fosamil-Clinpharm-PREA.pdf
27. Teflaro (ceftaroline) dosing, indications, interactions, adverse effects, and more, accessed August 6, 2025, https://reference.medscape.com/drug/teflaro-ceftaroline-999606
28. Use of Ceftaroline Fosamil in Osteomyelitis: CAPTURE Study Experience - PMC, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6385445/
29. Safety, local tolerability and pharmacokinetics of ceftaroline fosamil administered in a reduced infusion volume, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC4256619/
30. TEFLARO® (ceftaroline fosamil) Pediatric Treatment, accessed August 6, 2025, https://www.teflaro.com/pediatric
31. Summary of Ceftaroline Fosamil Clinical Trial Studies and Clinical Safety - Bohrium, accessed August 6, 2025, https://www.bohrium.com/paper-details/summary-of-ceftaroline-fosamil-clinical-trial-studies-and-clinical-safety/813288775965736962-9747
32. CANVAS 2: the second Phase III, randomized, double-blind study evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections | Request PDF - ResearchGate, accessed August 6, 2025, https://www.researchgate.net/publication/279406372_CANVAS_2_the_second_Phase_III_randomized_double-blind_study_evaluating_ceftaroline_fosamil_for_the_treatment_of_patients_with_complicated_skin_and_skin_structure_infections
33. Summary of Ceftaroline Fosamil Clinical Trial Studies and Clinical Safety | Request PDF - ResearchGate, accessed August 6, 2025, https://www.researchgate.net/publication/230749677_Summary_of_Ceftaroline_Fosamil_Clinical_Trial_Studies_and_Clinical_Safety
34. Off-label use of Ceftaroline Fosamil: a systematic review | Request PDF - ResearchGate, accessed August 6, 2025, https://www.researchgate.net/publication/334210991_Off-label_use_of_Ceftaroline_Fosamil_a_systematic_review
35. Off-label use of Ceftaroline Fosamil: a systematic review - AIR Unimi, accessed August 6, 2025, https://air.unimi.it/bitstream/2434/919552/3/Pani_Post%2Bprint_Off-label_2019.pdf
36. Evaluation of Ceftaroline, Vancomycin, Daptomycin, or Ceftaroline plus Daptomycin against Daptomycin-Nonsusceptible Methicillin-Resistant Staphylococcus aureus in an In Vitro Pharmacokinetic/Pharmacodynamic Model of Simulated Endocardial Vegetations | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed August 6, 2025, https://journals.asm.org/doi/10.1128/aac.00088-14
37. A Mini-Review on Ceftaroline in Bacteremia Patients with Methicillin-Resistant Staphylococcus aureus (MRSA) Infections - MDPI, accessed August 6, 2025, https://www.mdpi.com/2079-6382/8/1/30
38. Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review - PMC - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5499876/
39. pmc.ncbi.nlm.nih.gov, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6385445/#:~:text=The%20addition%20of%20ceftaroline%20fosamil,%2C%2014%5D%2C%20and%20ease%20of
40. Ceftaroline fosamil Withdrawn Phase 4 Trials for Osteomyelitis / Joint Infection Treatment, accessed August 6, 2025, https://go.drugbank.com/drugs/DB06590/clinical_trials?conditions=DBCOND0045558%2CDBCOND0014303&phase=4&purpose=treatment&status=withdrawn
41. Ceftaroline fosamil for the treatment of hospital-acquired pneumonia and ventilator-associated pneumonia - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/25956849/
42. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia - ERS Publications, accessed August 6, 2025, https://publications.ersnet.org/content/errev/32/170/230117
43. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/37852658/
44. TEFLARO® (ceftaroline fosamil) Safety Profile, accessed August 6, 2025, https://www.teflaro.com/safety/adverse-reactions
45. Teflaro™ (ceftaroline fosamil)-clean-labeling text-2010-11-08 Page 1 of 13 Reference ID - accessdata.fda.gov, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/200327s001lbl.pdf
46. Ceftaroline Fosamil Powder for Concentrate for Solution for Infusion - Pfizer, accessed August 6, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=15036
47. Reference ID: 3315700 This label may not be the latest approved by FDA. For current labeling information, please visit https://, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200327s009lbl.pdf
48. CEFTAROLINE FOSAMIL - Pfizer, accessed August 6, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=12787
49. Teflaro - Drug Summary - PDR.Net, accessed August 6, 2025, https://www.pdr.net/drug-summary/Teflaro-ceftaroline-fosamil-158
50. TEFLARO® (ceftaroline fosamil) for injection, for intravenous use - This label may not be the latest approved by FDA. For current labeling information, please visit https://www.fda.gov/drugsatfda, accessed August 6, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/200327s025lbl.pdf
51. TEFLARO® (ceftaroline fosamil) System Error, accessed August 6, 2025, https://www.teflaro.com/adult/treatment
52. Efficacy and Safety of Vancomycin, Linezolid, and Ceftaroline in the ..., accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/39996230/
53. Systematic review of ceftaroline fosamil in the management of patients with methicillin-resistant Staphylococcus aureus pneumonia, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10582922/
54. Effectiveness and Safety of Linezolid Versus Vancomycin, Teicoplanin, or Daptomycin against Methicillin-Resistant Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis - MDPI, accessed August 6, 2025, https://www.mdpi.com/2079-6382/12/4/697
55. Multicenter Cohort Study of Ceftaroline Versus Daptomycin for ..., accessed August 6, 2025, https://academic.oup.com/ofid/article/9/3/ofab606/6481735
56. Multicenter Cohort Study of Ceftaroline Versus Daptomycin for Treatment of Methicillin-Resistant Staphylococcus aureus Bloodstream Infection, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8825758/
57. Five Things To Know About Combination Therapy With Daptomycin ..., accessed August 6, 2025, https://www.idstewardship.com/five-things-know-combination-therapy-daptomycin-plus-ceftaroline-treatment-staphylococcus-aureus-bacteremia/
58. Clinical Data on Daptomycin plus Ceftaroline versus Standard of Care Monotherapy in the Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed August 6, 2025, https://journals.asm.org/doi/10.1128/aac.02483-18
59. Multicenter Cohort of Patients With Methicillin-Resistant Staphylococcus aureus Bacteremia Receiving Daptomycin Plus Ceftaroline Compared With Other MRSA Treatments | Open Forum Infectious Diseases | Oxford Academic, accessed August 6, 2025, https://academic.oup.com/ofid/article/7/1/ofz538/5691187
60. Penicillin-Binding Protein 3 Inserts in E.coli:A Growing Burden of Underreported Threat, accessed August 6, 2025, https://medicaldialogues.in/medicine/perspective/penicillin-binding-protein-3-inserts-in-ecolia-growing-burden-of-underreported-threat-152695
61. Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program - PMC - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC3370782/
62. Summary of Ceftaroline Activity against Pathogens in the United States, 2010: Report from the Assessing Worldwide Antimicrobial Resistance Evaluation (AWARE) Surveillance Program, accessed August 6, 2025, https://journals.asm.org/doi/abs/10.1128/aac.00330-12
63. Ceftaroline Potency Among 9 US Census Regions: Report From the 2010 AWARE Program | Clinical Infectious Diseases | Oxford Academic, accessed August 6, 2025, https://academic.oup.com/cid/article/55/suppl_3/S194/285835
64. Antimicrobial Activity of Ceftaroline Tested Against Staphylococci with Reduced Susceptibility to Linezolid, Daptomycin or Vanc - JMI Laboratories, accessed August 6, 2025, https://www.jmilabs.com/data/posters/IDWEEK2012/831.PDF
65. Reduced Ceftaroline Susceptibility among Invasive MRSA Infections in Children: a Clinical and Genomic Investigation | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed August 6, 2025, https://journals.asm.org/doi/abs/10.1128/aac.00745-22
66. In vitro Activity of Ceftaroline Against Isolates of Gram-Positive Bacteria from Patients with Bloodstream Infections Collected as a Part of ATLAS Between 2017 and 2020 - PubMed Central, accessed August 6, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC10838500/
67. Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022 | Antimicrobial Agents and Chemotherapy - ASM Journals, accessed August 6, 2025, https://journals.asm.org/doi/10.1128/aac.01402-24
68. Ceftaroline: Systematic Review of Clinical Uses and Emerging Drug Resistance - PubMed, accessed August 6, 2025, https://pubmed.ncbi.nlm.nih.gov/35300514/